Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23059749 | 0.95 | GPBAR1 (0.36) | GPBAR1ALDH1A1LMNAGAA | |
| SCHEMBL22520723 | 0.92 | GPBAR1 (0.42) | GPBAR1GAANPC1RAB9AALOX15 | |
| SCHEMBL23059612 | 0.91 | ALDH1A1 (0.35) | GPBAR1ALDH1A1LMNAGAANPC1 | |
| SCHEMBL23059614 | 0.90 | ALDH1A1 (0.33) | GPBAR1ALDH1A1LMNA | |
| SCHEMBL23059617 | 0.89 | GPBAR1 (0.40) | GPBAR1ALDH1A1LMNAGAATSHR | |
| SCHEMBL23059619 | 0.89 | ALDH1A1 (0.36) | GPBAR1ALDH1A1LMNAGAA | |
| SCHEMBL23059611 | 0.88 | GPBAR1 (0.40) | GPBAR1ALDH1A1LMNA | |
| SCHEMBL23059742 | 0.87 | GPBAR1 (0.36) | GPBAR1ALDH1A1LMNA | |
| SCHEMBL23059745 | 0.86 | GRM4 (0.34) | GPBAR1ALDH1A1LMNA | |
| SCHEMBL25085494 | 0.85 | GPBAR1 (0.35) | GPBAR1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065544-A1 | ISOPHTHALAMINDE COMPOUND AND USE THEREOF | Metisa Biotechnology Co., Ltd (CN) | 2023-03-02 | — | — | US | disclosed |
| WO-2021036965-A1 | ISOPHTHALAMIDE COMPOUND AND USE THEREOF | 沈阳化工大学 | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065544-A1 | ISOPHTHALAMINDE COMPOUND AND USE THEREOF | DDT, INMT, CYP2B6 | GPBAR1 952/4885ALDH1A1 105/4885LMNA 4164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.